German firm negotiates license deal over RA drug

10/18/2007 | Bloomberg1

German biotech company 4SC AG is negotiating with several drugmakers to license its drug SC12267 for rheumatoid arthritis, CEO Ulrich Dauer said. The firm says the drug, which targets autoimmune disorders, also has shown promise in treating multiple sclerosis and chronic bowel conditions.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY